Hsbc Holdings PLC Takes $1.05 Million Position in Kura Oncology, Inc. $KURA

Hsbc Holdings PLC bought a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the second quarter, HoldingsChannel reports. The institutional investor bought 94,810 shares of the company’s stock, valued at approximately $1,055,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after buying an additional 348,127 shares during the period. Hennion & Walsh Asset Management Inc. boosted its position in Kura Oncology by 69.7% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock valued at $6,240,000 after buying an additional 233,633 shares during the last quarter. UBS Group AG boosted its position in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after buying an additional 574,455 shares during the last quarter. Nan Fung Trinity HK Ltd. grew its stake in shares of Kura Oncology by 317.9% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock valued at $10,025,000 after acquiring an additional 734,000 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in shares of Kura Oncology by 285.6% during the first quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock valued at $1,291,000 after acquiring an additional 117,650 shares in the last quarter.

Insider Transactions at Kura Oncology

In other news, CEO Troy Edward Wilson acquired 100,000 shares of the business’s stock in a transaction on Monday, August 24th. The shares were purchased at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the completion of the purchase, the chief executive officer directly owned 479,194 shares of the company’s stock, valued at $5,937,213.66. This represents a 26.37% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian T. Powl sold 4,345 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.89, for a total value of $51,662.05. Following the transaction, the insider directly owned 169,269 shares in the company, valued at approximately $2,012,608.41. This represents a 2.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 120,761 shares of company stock valued at $1,283,346 over the last ninety days. 7.60% of the stock is currently owned by company insiders.

Kura Oncology Price Performance

Shares of KURA stock opened at $12.65 on Tuesday. The firm has a fifty day moving average of $10.91 and a two-hundred day moving average of $9.68. The firm has a market cap of $1.13 billion, a P/E ratio of -3.75 and a beta of 0.38. Kura Oncology, Inc. has a 1-year low of $7.36 and a 1-year high of $13.90. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on KURA shares. Morgan Stanley set a $24.00 target price on Kura Oncology in a research report on Monday, August 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Citizens Jmp restated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Jefferies Financial Group set a $24.00 target price on Kura Oncology in a research report on Thursday, May 28th. Finally, Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.